Comment
doi: 10.1056/NEJMc1909687.
Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply
Affiliations
- PMID: 31509685
- DOI: 10.1056/NEJMc1909687
Item in Clipboard
Comment
Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply
N Engl J Med.
.
No abstract available
Comment on
-
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.N Engl J Med. 2019 Sep 12;381(11):1087-1088. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509681 No abstract available.
-
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.N Engl J Med. 2019 Sep 12;381(11):1088. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509682 No abstract available.
-
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.N Engl J Med. 2019 Sep 12;381(11):1088-1089. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509683 No abstract available.
-
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.N Engl J Med. 2019 Sep 12;381(11):1089. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509684 No abstract available.
Similar articles
-
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.N Engl J Med. 2019 Sep 12;381(11):1089. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509684 No abstract available.
-
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.N Engl J Med. 2019 Sep 12;381(11):1088-1089. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509683 No abstract available.
-
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.N Engl J Med. 2019 Sep 12;381(11):1088. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509682 No abstract available.
-
Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.Nat Rev Nephrol. 2018 Feb;14(2):78-80. doi: 10.1038/nrneph.2017.182. Epub 2018 Jan 8. Nat Rev Nephrol. 2018. PMID: 29307892 Review. No abstract available.
-
Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.J Diabetes Complications. 2018 Jul;32(7):720-725. doi: 10.1016/j.jdiacomp.2018.04.011. Epub 2018 May 5. J Diabetes Complications. 2018. PMID: 29880432 Review.
Cited by
-
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.BMJ Open Diabetes Res Care. 2023 Jun;11(3):e003270. doi: 10.1136/bmjdrc-2022-003270. BMJ Open Diabetes Res Care. 2023. PMID: 37311602 Free PMC article. Clinical Trial.
-
Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials.Front Pharmacol. 2022 Oct 13;13:1009571. doi: 10.3389/fphar.2022.1009571. eCollection 2022. Front Pharmacol. 2022. PMID: 36313382 Free PMC article.
-
Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes.Heart Fail Rev. 2023 May;28(3):723-732. doi: 10.1007/s10741-021-10211-9. Epub 2022 Jan 31. Heart Fail Rev. 2023. PMID: 35098383 Free PMC article. Review.
-
Diagnosis codes underestimate chronic kidney disease incidence compared with eGFR-based evidence: a retrospective observational study of patients with type 2 diabetes in UK primary care.BJGP Open. 2024 Apr 25;8(1):BJGPO.2023.0079. doi: 10.3399/BJGPO.2023.0079. Print 2024 Apr. BJGP Open. 2024. PMID: 37709350 Free PMC article.
-
Clinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR Decline.Diabetes Metab Syndr Obes. 2022 Sep 16;15:2847-2856. doi: 10.2147/DMSO.S381052. eCollection 2022. Diabetes Metab Syndr Obes. 2022. PMID: 36148023 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
